HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
HemoGenyx Pharmaceuticals has made significant strides in the first half of 2024, with the FDA lifting the clinical hold on their HEMO-CAR-T treatment for acute myeloid leukemia, leading to a successful £3.325 million fundraising to initiate Phase I trials at MD Anderson Cancer Center. The company also reported progress in their CBR and CDX programs and a lower half-year loss compared to the previous year, due to favorable currency exchange rates and reduced R&D costs. As HemoGenyx moves into clinical trials, they are well-positioned for growth and look forward to offering new therapies for serious blood diseases.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.
